Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Explore this article's sources with AI

ChatGPTClaudePerplexityGeminiGrokGoogle AI

Follow PeptideMethods on Google

First published

Gaps in Obesity Medicine Prescribing

A 2026 paper reports persistent semaglutide and tirzepatide prescribing gaps in class III obesity, but an order is only one step in access.

Why we wrote this. Prescription counts are often mistaken for treatment access. This article separates the recorded order from dispensing, continuation and individual suitability.

In this article (5 sections)
  1. What class III obesity means
  2. Earlier US data showed low recorded uptake
  3. A prescribing gap has more than one possible cause
  4. What the evidence can support
  5. What we don't yet know

A 2026 paper reports persistent gaps in prescribing semaglutide and tirzepatide among US adults with class III obesity who did not have type 2 diabetes[1]. The finding is about prescribing, not prescriptions filled, treatment started, long-term use or clinical outcomes.

That distinction is central. A prescription record can show that a clinician ordered a medicine. It cannot show whether insurance approved it, a pharmacy dispensed it, the patient could afford it, or treatment continued. Earlier nationwide electronic-health-record research found low overall prescribing and differences by sex, race and ethnicity, social vulnerability and location[2].

What class III obesity means

Class III obesity is generally defined using a body mass index of 40 or higher. BMI is a screening measure rather than a complete assessment of health, but this category identifies a population with substantial obesity-related health risks on average. The 2026 paper specifically excluded people with type 2 diabetes, which helps separate obesity prescribing from diabetes treatment.

Excluding type 2 diabetes also changes how the data should be read. Semaglutide and tirzepatide products have different labeled indications and insurance rules. A database study focused on obesity should distinguish products prescribed for weight management from products prescribed for glucose control. Otherwise, diabetes treatment could be mistaken for obesity access.

Earlier US data showed low recorded uptake

A 2025 JAMA study used the Epic Cosmos electronic health record dataset. It included 39,060,622 adults with obesity, or overweight plus an obesity-related condition, and excluded type 2 diabetes. Between 2021 and 2024, 887,110 people, or 2.3%, had an obesity-specific prescription order for semaglutide or tirzepatide[2].

Prescribing differed across groups in that analysis. Recorded proportions were 3.0% for women and 1.2% for men. They were 2.6% in the least socially vulnerable quartile and 1.9% in the most vulnerable quartile, while metropolitan and rural proportions were 2.4% and 1.5%, respectively[2]. These are associations in records, not proof of why the differences occurred.

The researchers reported that prescription rates increased across all groups, yet disparities persisted. They also emphasized that absolute subgroup differences were smaller than the overall underuse[2]. This context matters for the new class III obesity report: a gap can involve both low use across the eligible population and unequal use between groups.

A prescribing gap has more than one possible cause

Electronic records usually cannot isolate one barrier. Insurance exclusions, prior authorization, shortages, local clinician capacity, patient preference, contraindications and out-of-pocket cost can all affect whether an order appears. Some people may decline medicine after an informed discussion. Others may want treatment but be unable to obtain it.

The correct interpretation is therefore not that every person in the denominator should receive a prescription. Eligibility starts a clinical conversation. Individual suitability still depends on medical history, current medicines, potential harms, expected benefits and the person's priorities. Equitable access means that avoidable barriers should not decide the outcome before that assessment can occur.

Prescribing also sits near the beginning of a treatment pathway. A useful access analysis would follow authorization, dispensing, initiation, persistence and follow-up. If a study measures only orders, it may count prescriptions that were denied or never collected. If it measures claims only, it can miss cash purchases and care outside the captured system.

What the evidence can support

The 2026 PubMed record establishes the paper's focus on persistent prescribing gaps in adults with class III obesity without type 2 diabetes[1]. The public record available at drafting did not include an abstract with the sample, subgroup estimates or observation period. We therefore do not assign numbers or causes to that paper that its accessible record does not report.

The earlier JAMA analysis supplies documented national context from a very large electronic-record repository[2]. It found low recorded prescribing and subgroup differences, but its authors noted that orders do not establish treatment status. Online-only pharmacies were also outside the collaborating institutions, so the dataset was broad rather than complete.

Neither observational study can show that a prescription would have been appropriate for each person. They can identify patterns worth investigating. Follow-up work can then test whether coverage policy, geography, clinical workflow or other barriers explain those patterns and whether changing a barrier improves access without weakening safety review.

What we don't yet know

The accessible record for the 2026 paper does not reveal how many adults were studied, which health systems contributed data, how class III obesity was identified, or whether the analysis separated semaglutide from tirzepatide. Full methods are needed before comparing its estimates with earlier work.

We also do not know from prescribing records how many orders were approved, dispensed or continued, why a clinician did not prescribe, or what patients preferred. Better access research should connect clinical records with pharmacy outcomes and coverage decisions while protecting privacy. Interviews can add reasons that billing fields cannot capture.

For an individual, population-level underprescribing does not answer whether either medicine is suitable. A qualified healthcare professional can review indications, contraindications and alternatives, while the insurer or pharmacy can clarify coverage and supply. Those are separate questions, and both affect real access.

This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.

Frequently asked

What is class III obesity?

Class III obesity is generally defined as a body mass index of 40 or higher. BMI is a screening measure and does not by itself describe an individual's full health status.

Does a prescription mean treatment started?

No. A prescription order does not show whether insurance approved it, a pharmacy dispensed it, the patient could afford it, or treatment continued.

Why exclude people with type 2 diabetes?

Excluding type 2 diabetes helps an obesity-prescribing analysis avoid counting medicine ordered primarily for glucose management as obesity treatment.

Do prescribing gaps prove discrimination?

No. Record-based associations can flag unequal patterns but usually cannot identify one cause. Coverage, cost, geography, clinical factors and patient preference may all contribute.

Sources

  1. [1]Class III obesity prescribing gaps, PubMed PMID 43003413Tier 1 · primary↩
  2. [2]US semaglutide and tirzepatide prescribing disparities, PMC12042086Tier 1 · primary↩

No revisions yet. First published .

About the editorial team

PeptideMethods is written and edited by the PeptideMethods Editorial Team and published by Digital Compass Group Ltd. The team is not made up of medical professionals; every health, regulatory or dosage claim on the site is tied to a primary source and is not a substitute for advice from a qualified clinician.

See our editorial policy and methodology for how we research, source and verify.